Drugs / RG-7636
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01522664 | Mar 2012 → Jun 2015 | melanoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7636 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109282 ↗ |
| Known as | DEDN6526A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01522664 ↗ |
| Route | Intravenous | “the recommended Phase II dose (RP2D) for DEDN6526A was 2.4 mg/kg intravenous (IV) q3w” PMID 31385109 ↗ Aug 2019 |
| Target | EDNRB | “Endothelin receptor ET-B binding agent” CHEMBL2109282 ↗ |